Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review

Abstract

Purpose

Insomnia is highly prevalent in older persons and significantly impacts quality of life, functional abilities, and health status. It is frequently treated with benzodiazepines or Z-drugs. Due to adverse events, an increased use of alternative sedative medications has been observed in older adults. We aimed to study the efficacy and safety of alternative sedative medications for treating insomnia in older people, excluding benzodiazepines and Z-drugs.

Methods

We conducted a systematic search of MEDLINE (PubMed), EMBASE, and the Cochrane Central register of Controlled Trials databases. We included randomized controlled trials and prospective and retrospective quasi-experimental studies, conducted in patients older than 65 years, without psychiatric or neurological comorbidities.

Results

The systematic search yielded 9483 articles, of which 24 were included in this review, describing nine different sleep medications in total. No clear beneficial impact on sleep could be demonstrated in studies investigating the impact of melatonin (n = 10), paroxetine (n = 1), diphenhydramine (n = 1), tiagabine (n = 2), and valerian (n = 1). Ramelteon slightly improved sleep latency (n = 4), while doxepin was found to provide a sustained sleep improvement with a safety profile that was comparable to placebo (n = 3). Suvorexant showed an improved sleep maintenance with only mild side effects (n = 1). One study detected increased adverse effects of trazodone after 3 months but did not evaluate the effect on sleep.

Conclusions

The overall level of evidence was limited, making it difficult to draw robust conclusions. Preliminary evidence points towards suvorexant, doxepin, and possibly ramelteon as effective and safe pharmacological alternatives for treating insomnia in older adults.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M (2008) Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 4(5):487–504

  2. 2.

    Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG (1995) Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 18(6):425–432

  3. 3.

    Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG (1999) Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep 22(Suppl 2):S366–S372

  4. 4.

    Maggi S, Langlois JA, Minicuci N, Grigoletto F, Pavan M, Foley DJ, Enzi G (1998) Sleep complaints in community-dwelling older persons: prevalence, associated factors, and reported causes. J Am Geriatr Soc 46(2):161–168

  5. 5.

    Association AP (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Publishing, Inc., Arlington

  6. 6.

    Ancoli-Israel S, Cooke JR (2005) Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53(7 Suppl):S264–S271. https://doi.org/10.1111/j.1532-5415.2005.53392.x

  7. 7.

    Roth T, Ancoli-Israel S (1999) Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation survey. II. Sleep 22(Suppl 2):S354–S358

  8. 8.

    Haimov I, Hanuka E, Horowitz Y (2008) Chronic insomnia and cognitive functioning among older adults. Behav Sleep Med 6(1):32–54. https://doi.org/10.1080/15402000701796080

  9. 9.

    Brassington GS, King AC, Bliwise DL (2000) Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 48(10):1234–1240

  10. 10.

    Stone KL, Ensrud KE, Ancoli-Israel S (2008) Sleep, insomnia and falls in elderly patients. Sleep Med 9(SUPPL. 1):S18–S22. https://doi.org/10.1016/S1389-9457(08)70012-1

  11. 11.

    Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD (2005) Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53(6):955–962. https://doi.org/10.1111/j.1532-5415.2005.53304.x

  12. 12.

    Shi L, Chen SJ, Ma MY, Bao YP, Han Y, Wang YM, Shi J, Vitiello MV, Lu L (2018) Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev 40:4–16. https://doi.org/10.1016/j.smrv.2017.06.010

  13. 13.

    Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA (2016) Review of safety and efficacy of sleep medicines in older adults. Clin Ther 38(11):2340–2372. https://doi.org/10.1016/j.clinthera.2016.09.010

  14. 14.

    Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV (2004) Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 27(7):1255–1273

  15. 15.

    Abad VC, Guilleminault C (2018) Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging 35(9):791–817. https://doi.org/10.1007/s40266-018-0569-8

  16. 16.

    Brewster GS, Riegel B, Gehrman PR (2018) Insomnia in the older adult. Sleep Med Clin 13(1):13–19. https://doi.org/10.1016/j.jsmc.2017.09.002

  17. 17.

    Albrecht JS, Wickwire EM, Vadlamani A, Scharf SM, Tom SE (2019) Trends in insomnia diagnosis and treatment among Medicare beneficiaries, 2006-2013. Am J Geriatr Psychiatry 27(3):301–309. https://doi.org/10.1016/j.jagp.2018.10.017

  18. 18.

    Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19(3):437–454. https://doi.org/10.1016/s0887-6177(03)00096-9

  19. 19.

    Zhong G, Wang Y, Zhang Y, Zhao Y (2015) Association between benzodiazepine use and dementia: a meta-analysis. PLoS One 10(5):e0127836. https://doi.org/10.1371/journal.pone.0127836

  20. 20.

    Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD (2016) Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 165(2):125–133. https://doi.org/10.7326/m15-2175

  21. 21.

    Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL (2012) Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One 7(11):e49113. https://doi.org/10.1371/journal.pone.0049113

  22. 22.

    Kang DY, Park S, Rhee CW, Kim YJ, Choi NK, Lee J, Park BJ (2012) Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health 45(4):219–226. https://doi.org/10.3961/jpmph.2012.45.4.219

  23. 23.

    Lai MM, Lin CC, Lin CC, Liu CS, Li TC, Kao CH (2014) Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc 89(5):589–594. https://doi.org/10.1016/j.mayocp.2014.01.021

  24. 24.

    American Geriatrics Society (2019) Updated AGS beers criteria(R) for potentially inappropriate medication use in older adults (2019). J Am Geriatr Soc 67(4):674–694. https://doi.org/10.1111/jgs.15767

  25. 25.

    Vijay A, Becker JE, Ross JS (2018) Patterns and predictors of off-label prescription of psychiatric drugs. PLoS One 13(7):e0198363. https://doi.org/10.1371/journal.pone.0198363

  26. 26.

    Atkin T, Comai S, Gobbi G (2018) Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev 70(2):197–245. https://doi.org/10.1124/pr.117.014381

  27. 27.

    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716

  28. 28.

    Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M (2011) Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 26(7):687–694. https://doi.org/10.1002/gps.2582

  29. 29.

    Avidan AY, Palmer LA, Doan JF, Baran RW (2010) Insomnia medication use and the probability of an accidental event in an older adult population. Drug Healthc Patient Saf 2(1):225–232. https://doi.org/10.2147/DHPS.S14955

  30. 30.

    Baskett JJ, Broad JB, Wood PC, Duncan JR, Pledger MJ, English J, Arendt J (2003) Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing 32(2):164–170

  31. 31.

    Fainstein I, Bonetto AJ, Brusco LI, Cardinali DP (1997) Effects of melatonin in elderly patients with sleep disturbance: a pilot study. Curr Ther Res Clin Exp 58(12):990–1000. https://doi.org/10.1016/S0011-393X(97)80066-5

  32. 32.

    Fan Y, Yuan L, Ji M, Yang J, Gao D (2017) The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: a randomized controlled trial. J Clin Anesth 39:77–81. https://doi.org/10.1016/j.jclinane.2017.03.023

  33. 33.

    Garfinkel D, Laudon M, Nof D, Zisapel N (1995) Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346(8974):541–544

  34. 34.

    Garzon C, Guerrero JM, Aramburu O, Guzman T (2009) Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res 21(1):38–42

  35. 35.

    Glass JR, Sproule BA, Herrmann N, Busto UE (2008) Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 28(2):182–188. https://doi.org/10.1097/JCP.0b013e31816a9e4f

  36. 36.

    Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D (2017) Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials. Am J Geriatr Psychiatry 25(7):791–802. https://doi.org/10.1016/j.jagp.2017.03.004

  37. 37.

    Jaiswal SJ, McCarthy TJ, Wineinger NE, Kang DY, Song J, Garcia S, van Niekerk CJ, Lu CY, Loeks M, Owens RL (2018) Melatonin and sleep in preventing hospitalized delirium: a randomized clinical trial. Am J Med 131(9):1110–1117.e1114. https://doi.org/10.1016/j.amjmed.2018.04.009

  38. 38.

    Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T (2010) Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 33(11):1553–1561. https://doi.org/10.1093/sleep/33.11.1553

  39. 39.

    Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T (2012) Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 13(2):133–138. https://doi.org/10.1016/j.sleep.2011.09.006

  40. 40.

    Lemoine P, Nir T, Laudon M, Zisapel N (2007) Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16(4):372–380. https://doi.org/10.1111/j.1365-2869.2007.00613.x

  41. 41.

    Mini LJ, Wang-Weigand S, Zhang J (2007) Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 5(3):177–184. https://doi.org/10.1016/j.amjopharm.2007.09.004

  42. 42.

    Reynolds ICF, Buysse DJ, Miller MD, Pollock BG, Hall M, Mazumdar S (2006) Paroxetine treatment of primary insomnia in older adults. Am J Geriatr Psychiatr 14(9):803–807. https://doi.org/10.1097/01.JGP.0000218327.21111.de

  43. 43.

    Richardson GS, Zammit G, Wang-Weigand S, Zhang J (2009) Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 70(4):467–476

  44. 44.

    Roth T, Seiden D, Wang-Weigand S, Zhang J (2007) A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23(5):1005–1014. https://doi.org/10.1185/030079907x178874

  45. 45.

    Roth T, Wright KP Jr, Walsh J (2006) Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep 29(3):335–341

  46. 46.

    Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7(4):312–318. https://doi.org/10.1016/j.sleep.2006.01.003

  47. 47.

    Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, Ereshefsky L, Lankford A, Roth T (2008) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 69(10):1557–1564

  48. 48.

    Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CA (2009) A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med 10(3):319–328. https://doi.org/10.1016/j.sleep.2008.02.001

  49. 49.

    Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N (2007) Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 23(10):2597–2605. https://doi.org/10.1185/030079907x233098

  50. 50.

    Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N (2010) Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 8:51. https://doi.org/10.1186/1741-7015-8-51

  51. 51.

    Walsh JK, Randazzo AC, Frankowski S, Shannon K, Schweitzer PK, Roth T (2005) Dose-response effects of tiagabine on the sleep of older adults. Sleep 28(6):673–676

  52. 52.

    Kishi T, Matsunaga S, Iwata N (2015) Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PLoS One 10(8):e0136910. https://doi.org/10.1371/journal.pone.0136910

  53. 53.

    European Medicine Agency (2008) Meeting highlights from the Committee for Medicinal Products for Human Use,27–30 May 2008. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use27-30-may-2008. Accessed September 1st 2019

  54. 54.

    Jaffer KY, Chang T, Vanle B, Dang J, Steiner AJ, Loera N, Abdelmesseh M, Danovitch I, Ishak WW (2017) Trazodone for insomnia: a systematic review. Innov Clin Neurosci 14(7–8):24–34

  55. 55.

    Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nóbrega OT (2014) Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatr 22(12):1565–1574. https://doi.org/10.1016/j.jagp.2013.12.174

  56. 56.

    Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G (2010) Effectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 11(6):505–511. https://doi.org/10.1016/j.sleep.2009.12.009

  57. 57.

    Taibi DM, Landis CA, Petry H, Vitiello MV (2007) A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 11(3):209–230. https://doi.org/10.1016/j.smrv.2007.03.002

  58. 58.

    Bent S, Padula A, Moore D, Patterson M, Mehling W (2006) Valerian for sleep: a systematic review and meta-analysis. Am J Med 119(12):1005–1012. https://doi.org/10.1016/j.amjmed.2006.02.026

  59. 59.

    Reynolds AC, Adams RJ (2019) Treatment of sleep disturbance in older adults. J Pharm Pract Res 49(3):296–304. https://doi.org/10.1002/jppr.1565

Download references

Acknowledgments

The authors wish to thank Magdalena Jans of the Medical Library for her help with the design of our search strings.

Author information

All the authors have made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data. All were involved with drafting the work or revising it critically for important intellectual content and have given final approval of the version published.

Correspondence to Jos Tournoy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Judith Sys and Simon Van Cleynenbreugel shared first authorship

Electronic supplementary material

ESM 1

(DOCX 25 kb).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sys, J., Van Cleynenbreugel, S., Deschodt, M. et al. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 76, 363–381 (2020). https://doi.org/10.1007/s00228-019-02812-z

Download citation

Keywords

  • Insomnia
  • Older adults
  • Aged
  • Hypnotics and sedatives
  • Antidepressant
  • Sleep